hypothesis: changing to Travatan Z therapy increases the tear film break up time of subjects
on Xalatan therapy presenting with ocular surface disease.
Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting
with ocular surface disease will be advised to switch their medication to Travatan Z. Test
results will be record at the day that the medication was changed and at follow-up to
determine if there is a measurable change in tear film break up, corneal staining and in the
Ocular Surface Disease Index.
- on Xalatan monotherapy from 1 t 18 months
- 18 years of age or older
- has been diagnosed with ocular surface disease
- special populations such as children, pregnant females, prisoners, etc.